An impressive array of Big Pharma backers have lined up to ensure Strand Therapeutics has the funding needed to take its mRNA ...

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Keros Therapeutics has shaken up its leadership structure as the bi | Keros has shaken up its leadership structure as the ...

Ryght AI traveled down country roads to find the newest member of its growing clinical trial site collection. | Ryght AI ...

Heartflow has pumped up its IPO ambitions, raising its proposal into the vicinity of $300 million. | After first pricing its ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

The Department of Health and Human Services (HHS) has announced a plan to end mRNA vaccine work funded by the Biomedical ...

Terns Pharmaceuticals is planning to stop investing in metabolic disease clinical development at the end of 2025, starting a countdown to potential deals for assets including a midphase oral obesity ...